Antibody drug conjugates (ADCs) are advancing through clinical development with increasing complexity in both formulation and ...

Patients with advanced platinum-resistant ovarian cancer whose disease had progressed on standard therapy experienced ...

The World's Strongest Man is happening this weekend, featuring a lineup of the strongest men from all over the world. One of ...

Posters highlight antigen-independent delivery, differentiated efficacy and broad payload versatility of ultra pH-sensitive ...

Key market opportunities for bispecific antibody drug conjugates (BsADCs) include their potential to revolutionize cancer treatment by targeting dual antigens, addressing tumor heterogeneity. With ...

Izalontamab brengitecan (iza-bren) is an antibody-drug conjugate and bispecific antibody undergoing evaluation in small cell ...

Trastuzumab pamirtecan, being developed under a 2023 partnership between BioNTech and DualityBio, elicited a 44.1% overall ...

"China's immune barrier has remained solid, thanks to a vaccination rate of over 90 percent for the measles, mumps and ...

Investigational ADC QLS5132 showed promising clinical benefit and manageable safety in Phase I trial patients with platinum-resistant ovarian cancer.

In a complex therapeutic landscape, WuXi AppTec is simplifying the path from discovery to patient. Find out how.

Office of Prescription Drug Promotion (OPDP) has stepped up its enforcement efforts regarding prescription drug promotion, ...